Pfizer

Lung cancer
#FDA #Non-small cell lung cancer (NSCLC) #Oncology #Orphan drugs #Pfizer

Orphan designated precision drug approved in US for NSCLC

The US Food and Drug Administration (FDA) has approved orphan drug encorafenib (Braftovi) with binimetinib (Mektovi) for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The FDA also approved the FoundationOne CDx (tissue) and FoundationOne Liquid CDx (plasma) as companion diagnostics for encorafenib with… Read More

#News #Regulatory

#Collaboration #Ginkgo Bioworks #Pfizer #RNA

Pfizer does $331 million deal with Ginkgo Bioworks

Ginkgo Bioworks has announced a collaboration with Pfizer focused on the discovery of RNA-based drug candidates.   In the collaboration, Pfizer will leverage Ginkgo's proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas. Ginkgo will receive an upfront payment and is eligible to… Read More

#Business & Investment #News

#AstraZeneca #Business #Pfizer #Quarterly review #Regulatory #Sanofi

Drug discovery quarterly review: Second quarter 2023  

As the second quarter of 2023 draws to a close, DDW’s Megan Thomas reviews key updates and results from three top pharmaceutical companies. Business updates   Pfizer reported second quarter 2023 revenues totalling $12.7 billion, a decrease of $15.0 billion, or 54%, compared to the prior year quarter, reflecting an operational… Read More

#Business & Investment #Exclusive Content #Regulatory

Close up of vaccine syringe
#BioNTech #Comirnaty #Covid-19 #Covid-19 vaccine #MHRA #Omicron #Pfizer

UK regulator approves Pfizer/BioNTech’s adapted Covid-19 vaccine

Approval has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA) for an adapted Pfizer/BioNTech Covid-19 vaccine that targets the Omicron XBB 1.5 subvariant. The new version of Comirnaty was found to meet the UK regulator’s standards of safety, quality and effectiveness and has… Read More

#News #Trending News

Breast cancer
#Arvinas #Breast cancer #Cancer research #Oncology #Pfizer #UK

ER degrader for breast cancer receives UK Innovation Passport

Arvinas and Pfizer UK have been awarded a UK Innovation Passport for vepdegestrant (ARV-471), an investigational PROTAC ER (estrogen receptor) degrader. It is intended for the treatment of patients with oestrogen receptor (ER)+/ human epidermal growth factor receptor (HER)2- locally-advanced breast cancer or metastatic breast cancer. The Innovation Passport is… Read More

#News #Regulatory

#FDA #Immunology / Virology & Vaccines #Pfizer #Pregnancy #Respiratory syncytial virus

FDA approves RSV vaccine to protect babies from birth

The US Food and Drug Administration (FDA) has approved the first vaccine for pregnant individuals to prevent respiratory syncytial virus (RSV) in infants. Pfizer’s Abrysvo (Respiratory Syncytial Virus Vaccine) was approved for use at 32-36 weeks gestational age of pregnancy to prevent lower respiratory tract disease (LRTD) and severe LRTD… Read More

#News #Regulatory

Multiple myeloma
#Accelerated assessment #Bispecific Antibodies #FDA #Immunotherapy #Myeloma #Pfizer #Phase II trial

FDA accelerates approval for multiple myeloma immunotherapy

The US Food and Drug Administration (FDA) has granted accelerated approval to Pfizer’s Elrexfio (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). The drug is approved in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory… Read More

#News #Regulatory

Preparing Covid-19 vaccine for injection
#BioNTech #Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #Moderna #Novavax #Pfizer #Vaccines

New Covid-19 vaccines ready to slow spread of EG.5

It is believed that new Covid-19 vaccines developed by Pfizer/BioNTech, Moderna and Novavax will be effective against the fast-spreading EG.5 strain. EG.5 or ‘Eris’ has been found in more than 50 countries. It is the most common and fastest growing Covid-19 subvariant in the US, estimated… Read More

#News #Trending News

#Acquisition #Biopharma #Biotechnology #CDMO #Cell and gene therapy #Cold chain #Drug development #GSK #Pfizer #Regulatory #Supply chain

New podcast: A business case for drug discovery

This is the latest episode of the free DDW narrated podcast, “A business case for drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “A deal in the making”, “Why project management… Read More

#News

#AstraZeneca #Drug development #FDA #GSK #HER2 #National Institute for Health and Care Excellence (NICE) #Pfizer #Regulatory

New episode: DDW Highlights 19 June

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs,… Read More

#News

#AstraZeneca #Drug development #FDA #GSK #HER2 #National Institute for Health and Care Excellence (NICE) #Pfizer #Regulatory

This week in drug discovery (12-16 June)  

News round-up for 5-9 June by DDW Multimedia Editor Megan Thomas.  Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs, which is a common theme throughout this week’s news highlights, including an FDA approval for Pfizer, a NICE recommendation… Read More

#News

Respiratory syncytial virus
#FDA #GSK #Immunology / Virology & Vaccines #Pfizer #Respiratory syncytial virus

GSK faces RSV vaccine threat from rival Pfizer  

An FDA approval for Pfizer’s Abrysvo respiratory syncytial virus (RSV) vaccine is likely to threaten GSK’s current hold on the market, according to GlobalData.  GSK received approval by the European Commision (EC) for its vaccine Arexvy, which targets the prevention of lower respiratory tract infections (LRTI) caused by RSV in… Read More

#News #Regulatory #Trending News

Vaccine
#FDA #Immunology / Virology & Vaccines #Pfizer #Phase III trial #Respiratory syncytial virus

FDA approves first vaccine for respiratory syncytial virus

The US Food and Drug Administration (FDA) has approved Pfizer’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine Abrysvo in individuals 60 years and older. Abrysvo is unadjuvanted and composed of two preF proteins selected to optimise protection against RSV A and B strains and… Read More

#News #Trending News

PD-L1 antibody
#Antibody #Cancer research #Collaboration #Merck #Oncology #Pfizer

Merck buys full rights to cancer drug Bavencio from Pfizer

Merck has bought the exclusive worldwide rights to develop, manufacture and commercialise anti PD-L1 antibody Bavencio (avelumab) from Pfizer. Merck will take full control of the global commercialisation of Bavencio through its affiliate Ares Trading. The transaction has also ended a long-term collaboration between Merck and Pfizer. The current profit… Read More

#Business & Investment #News

Discovery Park, Kent
#Life sciences #Neuroscience #Pfizer #Science and innovation park

UK Discovery Park plans centre of excellence for neuroscience

One the UK’s largest science and innovation parks has revealed plans to double in size as it celebrates its ten-year anniversary. Discovery Park, based near Sandwich in Kent, marked the milestone by announcing its plans for the next ten years, which include the creation of a national centre of excellence… Read More

#News